Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial

医学 拜瑞妥 肺栓塞 深静脉 安慰剂 外科 置信区间 血栓形成 静脉血栓形成 意向治疗分析 随机对照试验 内科学 华法林 心房颤动 替代医学 病理
作者
Walter Ageno,Lorenza Bertù,Eugenio Bucherini,Giuseppe Camporese,Francesco Dentali,Matteo Iotti,Gianfranco Lessiani,Roberto Parisi,Paolo Prandoni,Michelangelo Sartori,Adriana Visonà,Elisabetta Bigagli,Gualtiero Palareti
出处
期刊: [BMJ]
卷期号:379: e072623-e072623 被引量:58
标识
DOI:10.1136/bmj-2022-072623
摘要

OBJECTIVE: To compare two different treatment durations of rivaroxaban in patients with symptomatic isolated distal deep vein thrombosis (DVT). DESIGN: Randomised, double blind, placebo controlled clinical trial. SETTING: 28 outpatient clinics specialising in venous thromboembolism. PARTICIPANTS: 402 adults (≥18 years) with symptomatic isolated distal DVT. INTERVENTIONS: After receiving standard dose rivaroxaban for six weeks, participants were randomly assigned to receive rivaroxaban 20 mg or placebo once daily for an additional six weeks. Follow-up was for 24 months from study inclusion. MAIN OUTCOMES MEASURES: The primary efficacy outcome was recurrent venous thromboembolism during follow-up after randomisation, defined as the composite of progression of isolated distal DVT, recurrent isolated distal DVT, proximal DVT, symptomatic pulmonary embolism, or fatal pulmonary embolism. The primary safety outcome was major bleeding after randomisation until two days from the last dose of rivaroxaban or placebo. An independent committee adjudicated the outcomes. RESULTS: 200 adults were randomised to receive additional rivaroxaban treatment and 202 to receive placebo. Isolated distal DVT was unprovoked in 81 (40%) and 86 (43%) patients, respectively. The primary efficacy outcome occurred in 23 (11%) patients in the rivaroxaban arm and 39 (19%) in the placebo arm (relative risk 0.59, 95% confidence interval 0.36 to 0.95; P=0.03, number needed to treat 13, 95% confidence interval 7 to 126). Recurrent isolated distal DVT occurred in 16 (8%) patients in the rivaroxaban arm and 31 (15%) in the placebo arm (P=0.02). Proximal DVT or pulmonary embolism occurred in seven (3%) patients in the rivaroxaban arm and eight (4%) in the placebo arm (P=0.80). No major bleeding events occurred. CONCLUSIONS: Rivaroxaban administered for six additional weeks in patients with isolated distal DVT who had an uneventful six week treatment course reduces the risk of recurrent venous thromboembolism, mainly recurrent isolated distal DVT, over a two year follow-up without increasing the risk of haemorrhage. TRIAL REGISTRATION: EudraCT 2016-000958-36; ClinicalTrials.gov NCT02722447.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
吴比完成签到,获得积分20
1秒前
SS完成签到,获得积分10
1秒前
wu的应助被鱼鱼子采纳,获得10
2秒前
shuimu的应助被月儿采纳,获得10
2秒前
ljy发布了新的文献求助10
2秒前
2秒前
毛bobi完成签到,获得积分10
2秒前
molihuakai的应助被Yinxin_Bai采纳,获得10
3秒前
Benedicta完成签到 ,获得积分10
3秒前
4秒前
小葡完成签到,获得积分10
4秒前
ZeKaWa的应助被jkjkjkjkhs采纳,获得30
4秒前
5秒前
MCY完成签到,获得积分10
5秒前
zhangshao完成签到,获得积分10
5秒前
森一发布了新的文献求助10
6秒前
研友_VZG7GZ的应助被Dae采纳,获得10
6秒前
Glufo发布了新的文献求助10
6秒前
6秒前
今后的应助被高贵靖柔采纳,获得10
7秒前
猴奔完成签到,获得积分20
7秒前
13313发布了新的文献求助10
7秒前
搜集达人的应助被巫凝天采纳,获得10
7秒前
Akim的应助被yanmu采纳,获得10
7秒前
7秒前
8秒前
鱼鱼子完成签到,获得积分20
8秒前
8秒前
wgt发布了新的文献求助10
8秒前
8秒前
开关盒完成签到,获得积分10
8秒前
wxkwxkwxk完成签到,获得积分10
9秒前
9秒前
搜集达人的应助被碳酸饮料采纳,获得10
10秒前
Maestro_S的应助被Feiii采纳,获得10
10秒前
wwwww发布了新的文献求助10
11秒前
李爱国的应助被zcy采纳,获得10
12秒前
mingjuan完成签到 ,获得积分10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175305
求助须知:如何正确求助?哪些是违规求助? 9567104
关于积分的说明 21790215
捐赠科研通 7769825
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477268